Review Article
You have free access to this content Schnitzler’s syndrome: diagnosis, treatment, and follow-up
Abstract
Schnitzler’s syndrome is characterized by recurrent urticarial rash and monoclonal gammopathy, associated with clinical and biological signs of inflammation and a long-term risk of AA amyloidosis and overt lymphoproliferation. An extensive literature review was performed, and the following questions were addressed during an expert meeting: In whom should Schnitzler’s syndrome be suspected? How should the diagnosis of Schnitzler’s syndrome be established? How should a patient with Schnitzler’s syndrome be treated? How should a patient with Schnitzler’s syndrome be followed up?. A diagnosis of Schnitzler’s syndrome is considered definite in any patient with two obligate criteria: a recurrent urticarial rash and a monoclonal IgM gammopathy, and two of the following minor criteria: recurrent fever, objective signs of abnormal bone remodeling, elevated CRP level or leukocytosis, and a neutrophilic infiltrate on skin biopsy. It is considered probable, if only 1 minor criterion is present. In patients with monoclonal IgG gammopathies, diagnosis is definite if three minor criteria are present and possible if two are present. First-line treatment in patients with significant alteration of quality of life or persistent elevation of markers of inflammation should be anakinra. Follow-up should include clinical evaluation, CBC and CRP every 3Â months and MGUS as usually recommended.
- A. Simon1,Â
- B. Asli2,Â
- M. Braun-Falco3,Â
- H. De Koning4,Â
- J.-P. Fermand2,Â
- C. Grattan5,
- K. Krause6,Â
- H. Lachmann7,Â
- C. Lenormand8,Â
- V. Martinez-Taboada9,Â
- M. Maurer6,Â
- M. Peters10,Â
- R. Rizzi11,Â
- F. Rongioletti12,Â
- T. Ruzicka3,Â
- L. Schnitzler13,Â
- B. Schubert14,
- J. Sibilia15,Â
- D. Lipsker8
Article first published online: 9 MAR 2013
DOI:Â 10.1111/all.12129
© 2013 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd